RED EYE TRIPLE ACTION 1 %
POLYETHYLENE GLYCOL 400 : 1 % TETRAHYDROZOLINE HYDROCHLORIDE : 0.05 % · DIN 02518201 · JOHNSON & JOHNSON INC
Health Canada status: MARKETED
What is RED EYE TRIPLE ACTION?
RED EYE TRIPLE ACTION 1 % contains POLYETHYLENE GLYCOL 400 : 1 % TETRAHYDROZOLINE HYDROCHLORIDE : 0.05 %. It is listed in the Health Canada Drug Product Database under DIN 02518201, held by JOHNSON & JOHNSON INC, supplied as DROPS for OPHTHALMIC administration. Health Canada currently lists it as marketed, status dated 12-Sep-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02518201 |
|---|---|
| Brand name | RED EYE TRIPLE ACTION |
| Generic / active ingredient | POLYETHYLENE GLYCOL 400 : 1 % TETRAHYDROZOLINE HYDROCHLORIDE : 0.05 % |
| Manufacturer | JOHNSON & JOHNSON INC |
| Strength | 1 % |
| Dosage form | DROPS |
| Route of administration | OPHTHALMIC |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | S01GA52 TETRYZOLINE, COMBINATIONS |
| AHFS class | 52:32.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 12-Sep-2025 |
| Original market date | 2022-03-15 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code S01GA52 TETRYZOLINE, COMBINATIONS. 8 of 19 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| 8-SYMPTOM RELIEF | 0.25 % | SOLUTION | JUNO OTC INC | MARKETED | DIN 02448955 |
| ADVANCED RELIEF EYE DROPS | 1 % | SOLUTION | JUNO OTC INC | MARKETED | DIN 02344319 |
| ALLERGY EYE DROPS | 0.05 % | SOLUTION | JUNO OTC INC | MARKETED | DIN 02290596 |
| CLEAR EYES TRIPLE ACTION RELIEF | 0.6 % | SOLUTION | PRESTIGE BRANDS INC | MARKETED | DIN 02301687 |
| RED EYE WORKPLACE | 0.05 % | DROPS | JOHNSON & JOHNSON INC | MARKETED | DIN 02518228 |
| VISINE FOR ALLERGY 3 SYMPTOM RELIEF | 0.25 % | DROPS | JOHNSON & JOHNSON INC | MARKETED | DIN 02144093 |
| VISINE MULTI-SYMPTOM | 0.25 % | DROPS | JOHNSON & JOHNSON INC | MARKETED | DIN 02338602 |
| ADVANCED RELIEF EYE DROPS | 0.1 % | SOLUTION | KC PHARMACEUTICALS INC | APPROVED | DIN 02455293 |
| ALLERGY EYE DROPS | 0.25 % | DROPS | ALCON CANADA INC | CANCELLED POST MARKET | DIN 02248660 |
| ALLERGY EYE DROPS | 0.25 % | SOLUTION | KC PHARMACEUTICALS INC | APPROVED | DIN 02455285 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.